ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial ...

Emerging detalimogene profile supports potential first line use in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer with CIS LEGEND trial pivotal cohort completed ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in. On December 22, CRISPR Therapeutics released a comprehensive clinical update on zugocaptagene geleucel ...

LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25) 71% of patients with ...

More than 80% of patients whose multiple myeloma had progressed on standard chimeric antigen receptor (CAR) T-cell therapy responded to an investigational CAR T-cell agent, a small study from China ...

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting 83% overall response and 61% complete ...

"Treatment with TAR-200 has long-lasting effectiveness. More than 82 percent of patients achieved a complete response, and of those that initially responded to treatment, more than half showed no ...

Immix Biopharma announced significant results from its NEXICART-2 Phase 1/2 clinical trial of NXC-201 at the ASCO 2025 conference, achieving a complete response (CR) rate of 70% in patients with ...

The complete response (CR) rate to the combination of the interleukin (IL)-15 superagonist nogapendekin alfa inbakicept-pmln (Anktiva®) and bacillus Calmette-Guerin (BCG) in BCG-unresponsive nonmuscle ...

TAR-200 achieved an 82.4% overall complete response rate in BCG-unresponsive, high-risk NMIBC patients with CIS, with a 45.9% 12-month complete response rate. The median duration of response was 25.8 ...

enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported additional preliminary data from the pivotal cohort of its ...